TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 Ig… Read more
TRACON Pharmaceuticals Inc (TCON) - Total Liabilities
Latest total liabilities as of June 2024: $10.49 Million USD
Based on the latest financial reports, TRACON Pharmaceuticals Inc (TCON) has total liabilities worth $10.49 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TRACON Pharmaceuticals Inc - Total Liabilities Trend (2012–2023)
This chart illustrates how TRACON Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TRACON Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of TRACON Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kalium Lakes Ltd
AU:KLL
|
Australia | AU$308.00K |
|
TRIPADVISOR
BE:T6A
|
Germany | €1.79 Billion |
|
Panaxia Labs Israel Ltd
TA:HROD
|
Israel | ILA31.85 Million |
|
VILKYSKIU PIENINE (UDW.SG)
STU:UDW
|
Germany | €54.09 Million |
|
Centrais Electricas Brasileiras S.A.- Eletrobr?!s American Depositary Shares (Each representing one Preferred Share)
NYSE:EBRB
|
USA | $107.64 Billion |
|
FRBP
PINK:FRBP
|
USA | $2.46 Billion |
|
African Agriculture Holdings Inc
NASDAQ:AAGRW
|
USA | $41.77 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down TRACON Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TRACON Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TRACON Pharmaceuticals Inc (2012–2023)
The table below shows the annual total liabilities of TRACON Pharmaceuticals Inc from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $10.91 Million | -59.00% |
| 2022-12-31 | $26.62 Million | +79.34% |
| 2021-12-31 | $14.84 Million | +20.03% |
| 2020-12-31 | $12.37 Million | -19.82% |
| 2019-12-31 | $15.42 Million | -19.70% |
| 2018-12-31 | $19.21 Million | +0.33% |
| 2017-12-31 | $19.14 Million | +10.06% |
| 2016-12-31 | $17.39 Million | -22.84% |
| 2015-12-31 | $22.54 Million | -67.95% |
| 2014-12-31 | $70.34 Million | +153.38% |
| 2013-12-31 | $27.76 Million | +36.94% |
| 2012-12-31 | $20.27 Million | -- |